Meropenem: Difference between revisions
m (Protected "Meropenem": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 20: | Line 20: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Meropenem''' is an ultra-broad spectrum injectable [[antibiotic]] used to treat a wide variety of infections, including [[meningitis]] and [[pneumonia]]. It is a [[beta-lactam]] and belongs to the subgroup of [[carbapenem]], similar to [[imipenem]] and [[ertapenem]]. Meropenem was originally developed by [[Sumitomo Pharmaceuticals]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Merrem®''' and '''Meronem®'''. Other brand names include '''Mepem®''' (Taiwan) and '''Meropen®''' (Japan, Korea). It gained [[FDA]] approval in July 1996. It penetrates well into many tissues and body fluids including the [[cerebrospinal fluid]], [[bile]], [[heart valve]]s, [[lung]], and [[peritoneal]] fluid.<ref name=AHFS>{{ cite book | title= AHFS DRUG INFORMATION® 2006 | publisher= American Society of Health-System Pharmacists | date= 2006 | edition= 2006 ed }} </ref> | '''Meropenem''' is an ultra-broad spectrum injectable [[antibiotic]] used to treat a wide variety of infections, including [[meningitis]] and [[pneumonia]]. It is a [[beta-lactam]] and belongs to the subgroup of [[carbapenem]], similar to [[imipenem]] and [[ertapenem]]. Meropenem was originally developed by [[Sumitomo Pharmaceuticals]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Merrem®''' and '''Meronem®'''. Other brand names include '''Mepem®''' (Taiwan) and '''Meropen®''' (Japan, Korea). It gained [[FDA]] approval in July 1996. It penetrates well into many tissues and body fluids including the [[cerebrospinal fluid]], [[bile]], [[heart valve]]s, [[lung]], and [[peritoneal]] fluid.<ref name=AHFS>{{ cite book | title= AHFS DRUG INFORMATION® 2006 | publisher= American Society of Health-System Pharmacists | date= 2006 | edition= 2006 ed }} </ref> | ||
| Line 42: | Line 42: | ||
{{CephalosporinAntiBiotics}} | {{CephalosporinAntiBiotics}} | ||
[[Category:Carbapenem antibiotics]] | [[Category:Carbapenem antibiotics]] | ||
[[zh:美羅培南]] | [[zh:美羅培南]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 17:20, 9 August 2012
| File:Meropenem.svg | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Protein binding | Approximately 2%. |
| Elimination half-life | 1 hour |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C17H25N3O5S |
| Molar mass | 383.464 g/mol |
|
WikiDoc Resources for Meropenem |
|
Articles |
|---|
|
Most recent articles on Meropenem |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Meropenem at Clinical Trials.gov Clinical Trials on Meropenem at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Meropenem
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Meropenem Discussion groups on Meropenem Directions to Hospitals Treating Meropenem Risk calculators and risk factors for Meropenem
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Meropenem |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.[1]
Mechanism of action
Meropenem is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamases or cephalosporinases. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.[2] Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.
Indications
The spectrum of action includes many gram-positive and gram-negative bacteria and even some anaerobic bacteria. The overall spectrum is similar to imipenem although meropenem is more active against Enterobacteriaceae and less active against gram-positive bacteria. It is also very resistant to extended-spectrum beta lactamases but may be more susceptible to metallo-beta-lactamases.[1] However, meropenem should not be used to treat MRSA infections.
Administration
Meropenem must be administered intravenously. It is supplied as a white crystalline powder to be dissolved in 5% monobasic potassium phosphate solution.
Common adverse effects
The most common adverse effects are diarrhea (4.8%), nausea and vomiting (3.6%), injection-site inflammation (2.4%), headache (2.3%), rash (1.9%), and thrombophlebitis (0.9%).[2] Many of these adverse effects were observed in the setting of severely ill individuals who were already taking many medications. Meropenem also has a reduced potential for causing seizures in comparison with imipenem.
References
- Pages with script errors
- CS1 maint: Extra text
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Carbapenem antibiotics